---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-015108"
form_type: "8-K"
ticker: "ORMP"
cik: "0001176309"
company_name: "ORAMED PHARMACEUTICALS INC."
filed_at: "2024-02-20T23:59:59+00:00"
generated_at: "2026-06-05T22:46:01.521621+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Oramed plans new U.S. Phase 3 oral insulin trial after subpopulation analysis; JV with HTIT with $70M investment

## Summary
- HTIT completed Phase 3 for oral insulin in China, in final regulatory approval; JV definitive agreement with $70M from HTIT, $20M from Oramed.
- Oramed to initiate new Phase 3 U.S. oral insulin trial later 2024 under differentiated protocol after FDA discussions; earlier Phase 3 missed endpoints.
- Scilex issued $101.875M secured note to Oramed at SOFR+8.5%; repayment began Dec 2023; warrants for 13M Scilex shares at $0.01.
- Acquired PeriTech film-forming technology for topical/dermatology; entered exclusive licensing deal for royalty on net sales.

## SEC filing metadata
- accession: 0001213900-24-015108
- form_type: 8-K
- ticker: ORMP
- cik: 0001176309
- company_name: ORAMED PHARMACEUTICALS INC.
- filed_at: 2024-02-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1176309/000121390024015108/0001213900-24-015108-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1176309/000121390024015108/ea0200197-8k_oramed.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-015108
- JSON: https://secwatch.observer/filing/0001213900-24-015108.json
- Plain text: https://secwatch.observer/filing/0001213900-24-015108.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.